Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

Most Recent Videos

Bareburger CEO Responds to Shake Shack IPO
28:42 - Jan. 30 -- Bareburger CEO Euripides Pelekanos discusses how he will expand the Bareburger brand with Bloomberg's Pimm Fox on "Taking Stock."
  • How Apple Conquered China Market: Bloomberg West (01/30)
  • Should Amazon Spin Off Its Growing Cloud Business?
  • TripAdvisor's Top Pick: Chicago's Langham Hotel